A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Administration Phase 1 Clinical Trial to Evalute the Satety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamics of MT1013 Injection in Healthy Subjects
Latest Information Update: 01 Aug 2022
At a glance
- Drugs MT 1013 (Primary)
- Indications Calcium metabolism disorders; Phosphorus metabolism disorders
- Focus Adverse reactions
- Sponsors Shaanxi Micot Technology Co
- 28 Jul 2022 Status changed from active, no longer recruiting to completed.
- 05 Apr 2022 Planned End Date changed from 30 Jan 2022 to 30 Jun 2022.
- 05 Apr 2022 Status changed from recruiting to active, no longer recruiting.